Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Salix Pharma Receives US Patent For Rifaximin
Salix said that the patent provides protection until August 2019 for Rifaximin, which Salix markets in the US under the trade names Xifaxan (200mg) and Xifaxan550 (550mg). Salix
Salix said that the patent provides protection until August 2019 for Rifaximin, which Salix markets in the US under the trade names Xifaxan (200mg) and Xifaxan550 (550mg). Salix
The findings, presented by Boehringer Ingelheim Pharmaceuticals at the 58th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists in San Francisco, include data from a
Phoenix’s initial product launches in North America are expected to include private label finished goods using its antibiotic APIs, such as bacitracin and polymyxin B sulfate, two of
Mr Bergh brings with him 30 years career experience as president of neuroscience products at Eli Lilly, as well as general manager of five affiliates on four continents
The Supera Veritas system was developed by IDEV to deliver its self-expanding Supera interwoven nitinol stent, a novel stent platform designed for the treatment of biliary and peripheral
Following a detailed analysis of the efficacy and safety results from the RA programme, Roche and Biogen Idec have concluded that the overall benefit to risk profile of
Vect-Horus has revealed the publication of its first patent in the ‘Institut National de la Propriété Intellectuelle’ (INPI) on April 23, 2010 (publication number FR2937322). The patent aims
Accumetrics VerifyNow System helps physicians assess patients’ response to all major antiplatelet therapies such as aspirin, Ticlid, Plavix, Effient and GP IIb/IIIa inhibitors. As response to these drugs
Muparfostat (PI-88) is one of a new class of multi-targeted cytostatic cancer therapeutics. It is a novel anti-cancer compound with a mechanism as a heparan sulfate mimetic. Muparfostat
With the initiation of the Phase I clinical studies for this compound, Evotec will receive a milestone payment of EUR2m. The compound, which was discovered and optimised within